1.Investigation and Analysis on Teaching Effect of Medical Genetics Experiment in Seven-year Program
Fangjie CHEN ; Chunyi LI ; Xiaoming LI ; Chunlian JIN ; Fucai LI ; Yanyan ZHAO
Chinese Journal of Medical Education Research 2002;0(01):-
Questionnaire was made to investigate teaching effect and further improve teaching quality of medical genetics experiment.The results showed that the refined experimental contents and reasonable teaching methods were vital to the teaching effect.Furthermore,the ability of independent thinking and operating skills should be considerably emphasized.
2.Expression and clinical significance of IL-17-producing CD4+ T and IL-17-producing CD8+ T cells in the peripheral blood of lung cancer patients
Jianhong HUANG ; Yanfeng WANG ; Jinfang ZHAI ; Li SHI ; Wen SU ; Fucai HAN
Cancer Research and Clinic 2013;25(7):463-465
Objective To investigate the expression and clinical significance of Th17 and Tc17 cells in peripheral blood of lung cancer patients.Methods The percentages of Th17 cells and Tc17 cells in 60 lung cancer patients and 40 healthy controls were evaluated by flow cytometry analysis (FCM).Results The percentages of Th17 cells [(1.795±0.623) %] and Te17 cells [(0.865±0.357) %] in lung cancer group were significandy higher than those in controls [(1.405±0.256) %,(0.640 ±0.204) %],(t =28.944,P < 0.001,t =14.051,P < 0.001).Furthermore,there was a positive correlation between Th17 cells and Tc17 cells in the two groups (lung cancer group r =0.770,P < 0.05,control group r =0.532,P < 0.05).The percentages of Th17 cells and Tc17 cells were closely associated with clinical stage (F =4.882,P =0.011,F =3.633,P =0.033),but not connected with pathological types (P > 0.05,P > 0.05).Conclusion The overexpression of Th17 and Tc17 may be involved in the occurrence and development of lung cancer,which can be used as new indicators for immunologic function of lung cancer patients,and provide a reference in monitoring the disease.
3.Study on Relationship Between Chinese Budd-Chiari Syndrome and Factor Ⅴ Leiden Mutation
Bo FENG ; Ke XU ; Hong JIANG ; Chunyuan JIN ; Weineng FU ; Fucai LI ; Hong LI ; Hongying SU ; Xitong ZHANG
Journal of China Medical University 2001;30(1):53-55
Objective:Our aim was to study the relationship between factor v Leiden (FⅤL) mutation and Chinese Budd-Chiari syndrome (BCS). Methods:Twenty-nine BCS patients (25 patients with sporadic BCS,4 with familial BCS ),29 healthy persons were detected for FⅤL mutation with PCR-RFLP.Results: FⅤL mutation was detected in 3 of 4 patients with familial BCS. Two patients in A family and one patient in B family had FⅤL mutation. The mutation was heterozygous. The mutation frequency was 0.0517 in 29 pationts with BCS, 0.3750 in 4 with familial BCS.The frequency of FⅤL mutation in patients and healthy persons showed no statistical difference,but frequency of FⅤL mutation between patients with familial BCS and healthy persons showed significant difference.Conclusion:The FⅤL mutation was related to Chinese familial BCS, but not related to Chinese BCS.
4.The mutation and expression of MUS81 gene in laryngeal squamous cell carcinoma.
Chanyuan LI ; Shuyun WANG ; Haiming YUAN ; Wei LI ; Zizheng LI ; Xiaoyu LI ; Xing GUO ; Fucai LI
Chinese Journal of Medical Genetics 2008;25(5):560-565
OBJECTIVETo investigate the association of mutations and expression of MUS81 gene with the tumorigenesis and progression of laryngeal squamous cell carcinoma (LSCC).
METHODSPCR-SSCP and DNA sequencing were carried out to examine mutations at exons 9 and 10 of MUS81 gene in 42 LSCC samples, with paired adjacent normal laryngeal tissues (PANLs) as control. Semi-quantitative RT-PCR and Western blot were used to detect the expression of MUS81 gene in the specimens.
RESULTSNo mutation was detected in the control group. Among the 42 LSCC specimens, nineteen (45.2%) were found to harbor mutations, including 11(26.2%) occurring within exon 9, and 8 (19%) within exon 10. Seventeen (40.48%) samples showed lower mRNA level of the MUS81 gene (P<0.01), and same proportion of samples had lower protein level (P<0.01), suggesting that MUS81 gene was similarly down-regulated at both mRNA and protein levels in the LSCC samples. Furthermore, mutations of MUS81 gene did not significantly correlate with TNM stages, age and lymphoid node metastasis (P>0.05). Nor did the expression of MUS81 gene with the TNM stages, age and lymphoid node metastasis in LSCC (P>0.05).
CONCLUSIONMutations and abnormal expression of MUS81 gene in the LSCC tissues were observed, which suggested that abnormalities of MUS81 gene may play an important role in the tumorigenesis of LSCC.
Age Factors ; Base Sequence ; Carcinoma, Squamous Cell ; genetics ; pathology ; DNA-Binding Proteins ; genetics ; Endonucleases ; genetics ; Exons ; genetics ; Gene Expression Regulation, Neoplastic ; Humans ; Laryngeal Neoplasms ; genetics ; pathology ; Lymphatic Metastasis ; genetics ; Molecular Sequence Data ; Mutation ; Neoplasm Staging ; RNA, Messenger ; genetics ; metabolism
5.Evaluation of the Cantrell syndrome with MSCT
Li WANG ; Xujia LUO ; Fucai QIN ; Wei LI ; Li DONG ; Jingjing WANG ; Shuna XIAO
Journal of Practical Radiology 2018;34(3):362-365
Objective To evaluate the role of MSCT in diagnosing Cantrell syndrome.Methods Five patients with Cantrell syndrome were enrolled in this study retrospectively.All clinical data,especially imaging data were collected at enrolment.Maximum intensity projection(MIP),multi planar reconstruction(MPR)and volume rendering(VR)of the analysis method of MSCT were used to describe the characteristics of Cantrell syndrome.Results The age of 5 patients ranged from 2 days to 24 years,4(4/5)cases were Cantrell syndrome and 1(1/5)case was incomplete Cantrell syndrome,3(3/5)cases were confirmed by surgery.Five cases were all diagnosed as ectocardia,thoracocyllosis,pericardium defect and diaphragm defect with MSCT.Four had sternum dysplasia,abdominal wall defect, 3 had ventricular diverticulum,2 had umbilical hernia.Conclusion MSCT can be used in accurately diagnosing Cantrell syndrome in clinical work.
6.Research of the Consistency between Pathology and the Single and Combined Diagnosis of Negative Breast Cancer by Ultrasonography and Mammography
Fucai QIN ; Yinzhen LI ; Ming YE
Journal of Medical Research 2018;47(3):74-78
Objective To study the consistency between pathology and the single and combined diagnosis of negative breast cancer by ultrasonography and mammography.Methods 90 clinical case data of patients with palpable negative breast tumors and mammography revealed small calcifications were retrospective analyzed.All patients were received the high frequency ultrasound.The value of two methods and combined diagnosis in the diagnosis of breast cancer with palpation negative were compared,which the pathological biopsy was the gold standard.Results The pathological showed that there were 58 cases of benign tumors,32 cases of malignant tumors,10 cases of stage 0,18 cases of stage Ⅰ,4 cases of stage Ⅱ.The high frequency ultrasonography was consistent with pathological(Kappa =0.641).The AUC of diagnosiing the breast cancer was 0.775.The molybdenum target radiography was consistent with pathological (Kappa =0.725),and the AUC was 0.830.The high frequency ultrasonography combined with molybdenum target radiography was highly consistent with pathological(Kappa =0.879),and the AUC was 0.934.The accuracy of combined diagnosis was higher than that of high frequency ultrasound (P < 0.05) and molybdenum target radiography(P > 0.05).Conclusion The high frequency ultrasonography and molybdenum target radiography have advantages in the diagnosis of palpable negative breast cancer.The joint diagnosis helps to achieve complementary strengths,has high consistency with pathology,and help to improve the diagnostic accuracy.
7.Expression and clinical significance of breast cancer metastasis suppressor 1 mRNA in supraglottic laryngeal carcinoma.
Xiaoyu LI ; Xing GUO ; Fucai LI ; Xiaotian LI ; Chao GUAN ; Huaian YANG ; Zimin PAN ; Chanyuanz LI ; Zhong REN
Journal of Clinical Otorhinolaryngology Head and Neck Surgery 2008;22(6):241-244
OBJECTIVE:
To investigate the expression of breast cancer metastasis suppressor 1 (BRMS1) mRNA in supraglottic cancer and to evaluate its clinical significance.
METHOD:
The expression of BRMS1 mRNA was examined by using RT-PCR method which take beta-actin mRNA as reference template in 66 cases of supraglottic cancer tissues and their adjacent normal mucosa tissues (ANT).
RESULT:
The expression of BRMS1 mRNA in the tissues of supraglottic cancer is lower significantly than that in the tissues of ANT ( P<0.05). There is correlation between BRMS1 mRNA expression and the clinical stage, differentiation and cervical lymph node metastasis in the laryngeal supraglottic cancers (P<0.05). There is no correlation between BRMS1 mRNA expression and sex and age.
CONCLUSION
Expression of BRMS1 mRNA in supraglottic cancer is lower than that in adjacent normal mucosa. The decrease of BRMS1 mRNA expression may be related to clinical stage and low differentiation and lymph node metastasis of supraglottic laryngeal cancer.
Adult
;
Aged
;
Aged, 80 and over
;
Carcinoma, Squamous Cell
;
metabolism
;
pathology
;
Female
;
Humans
;
Laryngeal Mucosa
;
metabolism
;
pathology
;
Laryngeal Neoplasms
;
metabolism
;
pathology
;
Lymphatic Metastasis
;
Male
;
Middle Aged
;
Neoplasm Proteins
;
metabolism
;
RNA, Messenger
;
genetics
;
Repressor Proteins
8.Expression of gene BRMS1 and CD44v6 protein in supraglottic laryngeal carcinoma and its clinical significance.
Xing GUO ; Xiaoyu LI ; Fucai LI ; Shuai FENG ; Xiaotian LI ; Zimin PAN ; Chao GUAN ; Yan WANG ; Huaian YANG ; Xuejun JIANG
Journal of Clinical Otorhinolaryngology Head and Neck Surgery 2009;23(6):249-253
OBJECTIVE:
To investigate the expression of breast cancer metastasis suppressor 1 (BRMS1) and CD44v6 protein in supraglottic cancer and to evaluate its clinical significance.
METHOD:
The expression of BRMS1 protein and CD44v6 protein were examined by using immunohistochemical method in 70 cases of paraffin-embedded supraglottic cancer tissues and their surrounding laryngeal normal mucosa tissues (LNT).
RESULT:
The expression of BRMS1 protein in LNT of supraglottic cancer was positive, and the positive rate was 85.7% (60/70); in tumor tissue was negative or lower expression, and the positive rate was 35.7% (25/70). The expression of CD44v6 protein in tumor tissue of supraglottic cancer was positive, the positive rate was 82.9% (58/70), in LNT was negative. There was a significant difference in BRMS1 and CD44v6 protein expression between the supraglottic cancer tissue and LNT (P<0.01). The expression of BRMS1 and CD44v6 protein had correlation with clinical stage and pathologic differentiation and cervical lymph node metastasis of supraglottic cancer (P<0.01). No correlation was found between the two proteins expression and sex and age (P>0.05). The expression of BRMS1 protein was related to the expression of CD44v6 protein (r = -0.9042, P<0.01). Calculated by Kaplan-Meier method, there is no survival difference at 3-year between the group with positive BRMS1 protein expression and the group with negative BRMS1 protein expression in tumor tissues (P>0.05), there is a significant survival difference at 3-year between the group with positive CD44v6 protein expression and the group with negative CD44v6 protein expression in tumor tissues (P<0.05).
CONCLUSION
The expression of BRMS1 protein in supraglottic cancer is significantly decreased and the expression of CD44v6 protein in supraglottic cancer is significantly increased. The expression of BRMS1 protein and CD44v6 protein has a close relationship with pathologic differentiation and clinical stage and cervical lymph node metastasis of supraglottic cancer. Combined detection of the expression of them in supraglottic cancer may provide a significant parameter to judge the cervical lymph node metastasis of supraglottic cancer.
Adult
;
Aged
;
Aged, 80 and over
;
Carcinoma, Squamous Cell
;
metabolism
;
pathology
;
Female
;
Humans
;
Hyaluronan Receptors
;
metabolism
;
Laryngeal Neoplasms
;
metabolism
;
pathology
;
Lymphatic Metastasis
;
Male
;
Middle Aged
;
Neoplasm Proteins
;
metabolism
;
Neoplasm Staging
;
Prognosis
;
Repressor Proteins
9.Homozygous deletion of p16 and p15 genes in laryngeal squamous cell carcinoma.
Fucai LI ; Ning KANG ; Yinghui LI ; Guang HE ; Changkun LIN ; Xinghe SUN ; Hongming GAO ; Kailai SUN
Chinese Journal of Medical Genetics 2002;19(1):30-32
OBJECTIVETo assess the relationship of homozygous deletion status of p16 (MTS1/INK4a/CDKN2A), p15(MTS2/INK4b/CDKN2B) genes and laryngeal squamous cell carcinoma(LSCC) progression.
METHODSDNA was extracted from fresh tumors. Homozygous deletion of p16 exon 2(p16E2) in 80 cases of LSCC and p15 exon 2(p15E2) in 67 cases of LSCC were detected by the polymerase chain reaction technique.
RESULTSThe p16E2 deletion rate in 80 cases was 12.5%(10/80); the p15E2 deletion rate in 67 cases was 11.94%(8/67); the p16E2 and p15E2 codeletion rate in 67 cases was 5.97%(4/67).
CONCLUSIONHomozygous deletion of p16E2 and p15E2 is related with LSCC oncogenesis, and it may play a role to some extent in LSCC malignant progression.
Carcinoma, Squamous Cell ; genetics ; Cell Cycle Proteins ; Cyclin-Dependent Kinase Inhibitor p15 ; Cyclin-Dependent Kinase Inhibitor p16 ; genetics ; Gene Deletion ; Genetic Markers ; Genetic Predisposition to Disease ; Homozygote ; Humans ; Introns ; genetics ; Laryngeal Neoplasms ; genetics ; Polymerase Chain Reaction ; methods ; Transcription Factors ; genetics ; Tumor Suppressor Proteins
10.The study of expression of BRMS1 gene protein and the expression of BRMS1 gene promotor area methylation in supraglottic laryngeal carcinoma and its clinical significance.
Xiaoyu LI ; Yungang WU ; Yucai SUN ; Mengmeng HUANG ; Dengdian MA ; Jing XU ; Xing GUO ; Xuejun JIANG ; Chao GUAN ; Fucai LI
Journal of Clinical Otorhinolaryngology Head and Neck Surgery 2012;26(15):701-703
OBJECTIVE:
To investigate the expression of breast cancer metastasis suppressor 1 (BRMS1) gene protein and the expression of BRMS1 gene promotor area methylation in supraglottic cancer and to evaluate its clinical significance.
METHOD:
The expression of BRMS1 protein and BRMS1 gene promotor area methylation were examined by using Western blotting method and methylation-specific polymerase chain reaction(MSP) method in 70 cases of supraglottic cancer tissues and 60 cases of their surrounding laryngeal normal mucosa tissues (LNT) and 44 cases of cervical lymph node metastasis of supraglottic cancer.
RESULT:
Western blot results indicate that BRMS1 protein expression is declined expression level in supraglottic cancer tissue than the expression of BRMS1 protein in LNT of supraglottic cancer. Compared with para carcinoma normal laryngeal mucous tissue, BRMS1 gene protein in supraglottic cancer tissue primary lesion decreased obviously, and it is decreased more obviously in cervical lymph node metastasis lesion, the discrepancy is notable (P < 0.05). MSP results indicate BRMS1 gene promotor methylation is coordinated with its down-expression in supraglottic cancer tissue. BRMS1 promotor area methylation analysis reveal that there were 34 patients with methylation in 70 patients' supraglottic cancer tumor primary lesion, hold 48.6% (34/70); 32 patients have methylation in 44 patients' cervical metastasis lymph node tissue, hold 72.7% (32/44); however, there is no methylation in 60 para carcinoma tissue (r(s) = 0.66, P < 0.05).
CONCLUSION
The expression of BRMS1 protein in supraglottic cancer is significantly decreased. It had correlation with clinical stage and pathologic differentiation and cervical lymph node metastasis of supraglottic cancer. BRMS1 gene promotor methylation is related with down-expression of BRMS1 gene protein of supraglottic cancer. Maybe BRMS1 gene promotor methylation is one of the reasons of its down-expression.
Adult
;
Aged
;
Aged, 80 and over
;
Carcinoma, Squamous Cell
;
metabolism
;
pathology
;
DNA Methylation
;
Female
;
Glottis
;
Head and Neck Neoplasms
;
metabolism
;
pathology
;
Humans
;
Laryngeal Neoplasms
;
metabolism
;
pathology
;
Lymph Nodes
;
pathology
;
Lymphatic Metastasis
;
Male
;
Middle Aged
;
Neoplasm Proteins
;
metabolism
;
Neoplasm Staging
;
Promoter Regions, Genetic
;
RNA, Messenger
;
genetics
;
Repressor Proteins
;
Squamous Cell Carcinoma of Head and Neck